En este episodio de Lung Cancer Considered, vamos a hablar sobre el cancer de pulmón en México. Tengo el placer de tener en este episodio dos doctores con mucha experiencia tratando y entendiendo las necesidades de los pacientes con cancer de pulmón en México. Este episodio es una introducción y esperamos tener conversaciones as profundas en el futuro.

Bio: Tenemos al Dr. Jorge Alatorre, Oncology clínico con Alta especialidad en Tumores del Tórax (Cáncer de pulmón y Mesotelioma). Y es jefe del Servicio de Oncología Médica del Instituto Nacional de Enfermedades Respiratorias (INER). También ofrece consulta en el Centro Médico ABC Santa Fe y en ONCARE ubicados en la Ciudad de México

Bio: Dr. Silviano Rios, Cirujano torácico de la ciudad de Monterrey en México. Atiende a sus pacientes en el Hospital Zambrano Hellion y TecSalud y se especializa en cirugía mínimamente invasiva.

Description: As part of IASLC’s commitment to communicating in all world languages, this episode of Lung Cancer Considered is recorded in German and is part of our Virtual Tumor Board series. Host Professor Alessandra Curioni-Fontecedro moderates a discussion with two colleagues, who will discuss the dynamic topic of managing resectable stage III NSCLC.

Host: Prof Alessandra Curioni-Fontecedro, MD, Head of Oncology, Cantonal Hospital Fribourg, Chair of Medical Oncology, University of Fribourg

Guest: Prof. Isabelle Opitz, Professor of Thoracic Surgery and Director of the Department of Thoracic Surgery at University Hospital of Zurich, Chair of the Lung Cancer Center of Zurich, and the past President of the European Society of Thoracic Surgery. She received the IASLC Robert J Ginsberg Lectureship Award for Surgery at the 2022 World Conference on Lung Cancer

Guest: Prof. Michael Thomas, Chefarzt of Dept of Thoracic Oncology at the Thoraxklinik Heidelberg, Germany.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu discusses the recent FDA approval of zenocutuzumab for NSCLC with an NRG1 fusion. NRG1 fusions are rare but important events seen in many cancer types, including NSCLC. Zenocutuzumab is a HER2/HER3 bispecific antibody that showed clear efficacy in NSCLC and in pancreatic cancer that harbored an NRG1 fusion.

Guest: Dr. Alison Schram, Assistant Attending Physician and Section Head of Oral Therapeutics in Early Drug Development at Memorial Sloan Kettering Cancer Center in New York

ESMO Immuno-Oncology Congress 2024 Highlights

Description: In this episode of Lung Cancer Considered, host Dr. Narjust Florez and Dr. Alfredo Addeo discuss some of the data presented at The ESMO Immuno-Oncology Congress 2024, which took place in December 2024 in Geneva, Switzerland.

Guest: Dr. Alfredo Addeo, Professor and Chief of Oncology, University Hospital of Geneva

Preview: 2025 Pan-Africa Lung Cancer Meeting

The 2025 Pan-Africa Lung Cancer Conference will take place January 31 - February 1, 2025, in Accra, Ghana and represents the first IASLC multidisciplinary lung cancer conference in Sub-Saharan Africa. In this episode of Lung Cancer Considered, host Dr. Narjust Florez talks with the conference co-chairs about this groundbreaking meeting and what attendees will experience at the meeting.

Guest: Dr. Chukwumere E. Nwogu is a Professor of Surgery at Roswell Park Cancer Institute and the University at Buffalo Jacobs School of Medicine & Biomedical Sciences

Guest: Dr. Jane Sandra Afriyie-Mensah is a Senior Pulmonologist and a Distinguished Academic and Researcher, currently affiliated with the University of Ghana and Korle Bu Teaching Hospital.

X: NA

Lung Cancer Considered host Dr. Stephen Liu and two distinguished thoracic oncologists review the highlights from the recently completed ESMO Asia 2024 meeting, held in Singapore. The episode covers a number of trials, including an update on FLAURA2, TROPION-Lung01 and TROPION-Lung05, ALESIA, and PACIFIC 5.

Guest: Dr. Misako Nagasaka, Associate Professor from the University of California, Irvine

Guest: by Dr. Molly Li, Clinical Assistant Professor from Chinese University of Hong Kong.

In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a discussion on the FDA approval of perioperative nivolumab based on the Phase III CheckMate 77T study. Perioperative therapy has improved outcomes in patients with resectable NSCLC and is emerging as best practice but there is nuance to the delivery of this therapy.

Guest: Dr. Tina Cascone is a Physician-Scientist and Associate Professor in the Department of Thoracic/Head and Neck Medical Oncology at the University of Texas MD Anderson Cancer Center in Houston, Texas and lead author of the CheckMate 77T manuscript in the New England Journal of Medicine

Guest: Dr. Shun Lu is the Chief of Shanghai Lung Cancer Center and Shanghai Chest Hospital and Professor at Shanghai Jiaotong University. He is an executive board member of the Chinese Society of Clinical Oncology and past chair of Chinese Lung Cancer Association

Tumor Treating Fields (TTFields) is a non-invasive cancer treatment that uses alternating electric fields to disrupt the ability of cancer cells to divide. TTFields can slow down tumor growth and spread, and may help people live longer than chemotherapy alone. In this episode of Lung Cancer Considered, host Dr. Narjust Florez discusses this new therapy and the Phase III LUNAR study that led to its FDA approval.

Guest: Dr. Ticiana Leal is an Associate Professor and serves as Director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine.

In this episode of Lung Cancer Considered host Dr. Narjust Florez discusses the future of lung cancer research in Brazil and the largest lung cancer screening program in South America. The episode was recorded during the IASLC 2024 Latin America Conference on Lung Cancer held in Bogota, Columbia.

Guests: Clarissa Baldotto is a Medical ) Oncologist at D’Or Rio De Janeiro and President Elect for the Brazilian Society of Clinical Oncology (SBOC)

Guest: Dr. Francisco Sarmento is a Thoracic Radiologist from Hospital Royal Portuguese in Brazil.

Lung Cancer Considered in German by IASLC